| Expression pattern: |
UP |
| Associated gene: |
AR, SLCO1B7, NcoR1, TPD52, RISC |
| Associated microRNA: |
miR-1295, miR-139-5p, miR-671-5p |
| Biological function: |
enhances invasion and decreases cisplatin response in lung cancer cells; promotes lung cancer progression |
| Molecular mechanism: |
AR transcriptionally represses circ-SLCO1B7 via binding to SLCO1B7 promoter ARE1/2 (with NcoR1); circ-SLCO1B7 acts as a miRNA sponge for miR-139-5p, relieving repression of TPD52 |
| Biological pathway or process: |
invasion (promotes); migration (promotes); drug resistance (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; RT-qPCR; RNA Pull-Down; Luciferase Reporter Assay; Transfection; MTT; Transwell Assay; Western Blot; ChIP / ChIP-seq; Co-IP; Clinical Sample Validation; Bioinformatics Analysis; In Vivo Animal Model; IHC (Immunohistochemistry); H&E Staining |
| Clinical significance: |
circ-SLCO1B7 expression correlates with tumor size, T grade, N grade, and differentiation; increased in lung cancer tissues vs adjacent normal tissues |
| Description: |
circ-SLCO1B7 is up-regulated in lung cancer tissues and promotes lung cancer cell invasion while reducing cisplatin response. Mechanistically, it acts as a ceRNA that sponges miR-139-5p to increase TPD52, and its transcription is repressed by AR via binding the SLCO1B7 promoter (ARE1/2, with NcoR1), forming an AR/circ-SLCO1B7/miR-139-5p/TPD52 axis validated in cells, clinical specimens, and an in vivo xenograft model. |
| Confidence score: |
0.8494 |